X
Cash round sets up trial of InteRNA’s microRNA for cancer
https://pharmaphorum.com/news/cash-round-sets-up-trial-of-internas-microrna-for-cancer/
solid tumour
Novartis’ severe aplastic anaemia drug fast-tracked by FDA
The FDA has accepted Novartis’ supplemental New Drug Application (sNDA) and granted Priority Review designation to Promacta (eltrombopag) in combination with standard immunosuppressive therapy (IST) for first-line treatment of severe aplastic anaemia (SAA), a rare and serious blood condition.